Metabolic subtyping for novel personalized therapies against pancreatic cancer

Kamiya Mehla, Pankaj K. Singh

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

Through metabolic subtyping, metabolic vulnerabilities can be exploited for developing efficacious treatments. A glycolytic subtype indicates poor survival in patients with pancreatic cancer, whereas a cholesterogenic subtype correlates with better outcomes potentially due to more energy expenditure. Personalized medicine holds great promise for improving therapy outcomes by optimally targeting metabolic pathways.

Original languageEnglish (US)
Pages (from-to)6-8
Number of pages3
JournalClinical Cancer Research
Volume26
Issue number1
DOIs
StatePublished - Jan 1 2020

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Metabolic subtyping for novel personalized therapies against pancreatic cancer'. Together they form a unique fingerprint.

  • Cite this